ArticleKidney medicine2026
Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Chronic kidney disease (CKD) poses an increasing global burden for patients and health care providers, driven by aging populations and the rising prevalence of chronic diseases. Despite strong evidence supporting benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2is), uptake remains limited. The objective of this study was to model potential benefits of increased SGLT2i uptake on clinical and economic outcomes of CKD in Denmark. Study Design: A dynamic decision-analytic modeling study with a 10-year time horizon. Setting & Participants: Danish incident and prevalent populations with CKD stages G3-G5 eligible for SGLT2is. Exposure: SGLT2i treatment with uptake rates of 15%, 50%, and 90%. Assumptions about SGLT2i treatment effects were based on the EMPA-KIDNEY trial. Outcomes: The model evaluated benefit on all-cause mortality, quality-adjusted life years, cardiovascular disease, and kidney failure (KF). The broader health care impact was estimated through costs and net monetary benefit. Analytical Approach: A validated Markov state microsimulation model (CKD progression model) using 18 health states, defined by eGFR and urinary albumin-creatinine ratio thresholds defined by Kidney Disease: Improving Global Outcomes (KDIGO). Results: Based on prevalence and incidence of CKD, the model predicts a 30% increase in the population of individuals with CKD stages G3-G5 from 251,946 in 2026 to 328,414 in 2035 with the current practice. SGLT2i uptake of 15%, 50%, and 90% are associated with a 10-year risks of KF of 8.5%, 6.6%, and 4.5%, respectively, and 10-year mortality rate of 54.3%, 53.9%, and 53.5%. This results in a net monetary benefit of 204 and 438 million €, respectively, compared with uptake of 15%. Limitations: The efficacy of SGLT2is was derived from a single randomized controlled trial. Conclusions: Based on a validated CKD progression model, increased SGLT2i uptake in Denmark is associated with increased patient survival and reduced progression to KF, leading to a net benefit on health care spending within a 6-year time horizon.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.